BACKGROUND: Ara h 2 and Ara h 6, co-purified together in a 13-25 kD fraction (Ara h 2/6; 20 kD fraction) on gel filtration chromatography, account for the majority of effector activity in a crude peanut extract (CPE) when assayed with RBL SX-38 cells sensitized with IgE from human peanut allergic sera. OBJECTIVES: To determine if Ara h 2/6 are the primary peanut allergens responsible for allergic reactions in vivo and to determine if Ara h 2/6 would be sufficient to prevent allergic reactions to a complete CPE. METHODS: An oral sensitization mouse model of peanut allergy was used to assess the activity of Ara h 2/6 (20 kD) and CPE without the 20 kD fraction (CPE w/o 20 kD) for allergic provocation challenge and immunotherapy. The activity of these preparations was also tested in an assay of histamine release from human basophils in whole blood. RESULTS: Compared with mice challenged with control CPE, mice challenged with CPE w/o 20 kD experienced reduced symptoms (P < 0.05) and a smaller decrease in body temperature (P < 0.01). Results with the basophil histamine release assay corroborated these findings (P < 0.01). The mouse model was also used to administer Ara h 2/6 (20 kD) in an immunotherapy protocol, in which peanut-allergic mice treated with the 20 kD fraction experienced significantly reduced symptoms, changes in body temperature, and mast cell protease (MMCP-1) release compared with placebo (P < 0.01 for all parameters). Importantly, immunotherapy with the 20 kD fraction was just as effective as treatment with CPE, whereas CPE w/o 20 kD was significantly less effective for higher dose peanut challenges. CONCLUSIONS AND CLINICAL RELEVANCE: Ara h 2/6 are the most potent peanut allergens in vivo and can be used to desensitize peanut-allergic mice. These results have potential implications for clinical research in the areas of diagnosis and immunotherapy for peanut allergy.
BACKGROUND:Ara h 2 and Ara h 6, co-purified together in a 13-25 kD fraction (Ara h 2/6; 20 kD fraction) on gel filtration chromatography, account for the majority of effector activity in a crude peanut extract (CPE) when assayed with RBL SX-38 cells sensitized with IgE from humanpeanut allergic sera. OBJECTIVES: To determine if Ara h 2/6 are the primary peanut allergens responsible for allergic reactions in vivo and to determine if Ara h 2/6 would be sufficient to prevent allergic reactions to a complete CPE. METHODS: An oral sensitization mouse model of peanut allergy was used to assess the activity of Ara h 2/6 (20 kD) and CPE without the 20 kD fraction (CPE w/o 20 kD) for allergic provocation challenge and immunotherapy. The activity of these preparations was also tested in an assay of histamine release from human basophils in whole blood. RESULTS: Compared with mice challenged with control CPE, mice challenged with CPE w/o 20 kD experienced reduced symptoms (P < 0.05) and a smaller decrease in body temperature (P < 0.01). Results with the basophil histamine release assay corroborated these findings (P < 0.01). The mouse model was also used to administer Ara h 2/6 (20 kD) in an immunotherapy protocol, in which peanut-allergic mice treated with the 20 kD fraction experienced significantly reduced symptoms, changes in body temperature, and mast cell protease (MMCP-1) release compared with placebo (P < 0.01 for all parameters). Importantly, immunotherapy with the 20 kD fraction was just as effective as treatment with CPE, whereas CPE w/o 20 kD was significantly less effective for higher dose peanut challenges. CONCLUSIONS AND CLINICAL RELEVANCE: Ara h 2/6 are the most potent peanut allergens in vivo and can be used to desensitize peanut-allergic mice. These results have potential implications for clinical research in the areas of diagnosis and immunotherapy for peanut allergy.
Authors: Xiu-Min Li; Kamal Srivastava; James W Huleatt; Kim Bottomly; A Wesley Burks; Hugh A Sampson Journal: J Immunol Date: 2003-03-15 Impact factor: 5.422
Authors: X M Li; D Serebrisky; S Y Lee; C K Huang; L Bardina; B H Schofield; J S Stanley; A W Burks; G A Bannon; H A Sampson Journal: J Allergy Clin Immunol Date: 2000-07 Impact factor: 10.793
Authors: G William Palmer; Donald A Dibbern; A Wesley Burks; Gary A Bannon; S Allan Bock; Harry S Porterfield; Robert A McDermott; Stephen C Dreskin Journal: Clin Immunol Date: 2005-06 Impact factor: 3.969
Authors: Andrew T Stefka; Taylor Feehley; Prabhanshu Tripathi; Ju Qiu; Kathy McCoy; Sarkis K Mazmanian; Melissa Y Tjota; Goo-Young Seo; Severine Cao; Betty R Theriault; Dionysios A Antonopoulos; Liang Zhou; Eugene B Chang; Yang-Xin Fu; Cathryn R Nagler Journal: Proc Natl Acad Sci U S A Date: 2014-08-25 Impact factor: 11.205
Authors: Ramon Bencharitiwong; Hanneke P M van der Kleij; Stef J Koppelman; Anna Nowak-Węgrzyn Journal: Allergy Asthma Proc Date: 2015 May-Jun Impact factor: 2.587
Authors: Audrey E Koid; Martin D Chapman; Robert G Hamilton; Ronald van Ree; Serge A Versteeg; Stephen C Dreskin; Stef J Koppelman; Sabina Wünschmann Journal: J Agric Food Chem Date: 2013-12-26 Impact factor: 5.279